Similar results were obtained with the Rho kinase (ROCK) inhibitor, fasudil, which was also shown to prevent MMP-9-related HT in mice treated with tPA (Table 2) (Ishiguro et al., 2012). The gene discussed is MMP9; the disease is hematocrit.